Impact of Valganciclovir Prophylaxis Duration on Cytomegalovirus Disease in High-Risk Donor Seropositive/Recipient Seronegative Heart Transplant Recipients

BACKGROUND: Few data support current guideline recommendations for 6 months over 3 months of antiviral prophylaxis for cytomegalovirus (CMV) disease prevention in donor seropositive/recipient seronegative (D+R-) heart transplant recipients (HTR). METHODS: We retrospectively assessed CMV disease and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transpl Infect Dis
Autors principals: Imlay, Hannah, Carcoana, Allison O. Dumitriu, Fisher, Cynthia E., Wong, Beatrice, Rakita, Robert M., Fishbein, Daniel P., Limaye, Ajit P.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284827/
https://ncbi.nlm.nih.gov/pubmed/32020736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tid.13255
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars